COMMUNIQUÉS West-GlobeNewswire
-
EssilorLuxottica: Second-Quarter and First-Half 2026 Results Conference Call Invitation
16/07/2026 -
Society for Medical Decision Making Honors UMIT TIROL and Harvard Professor Uwe Siebert with 2026 Career Achievement Award
16/07/2026 -
EssilorLuxottica: Second-Quarter and First-Half 2026 Results Conference Call Invitation
16/07/2026 -
Trethera and UCLA Publish Comprehensive Review Highlighting Deoxycytidine Kinase as a Novel Metabolic Target for Cancer Therapy
16/07/2026 -
La Croix-Rouge canadienne vient en aide aux communautés frappées par les inondations à Ottawa
16/07/2026 -
Canadian Red Cross supports communities impacted by Ottawa flooding
16/07/2026 -
NativePath 2026: Launch Effective Native Path Creatine Supplements for Seniors To Support Muscle Building and Strength with L-Leucine in USA
16/07/2026 -
Marius Pharmaceuticals Welcomes Department of Defense's New Testosterone Screening Initiative for U.S. Service Members
16/07/2026 -
SRX Global Regains Full Compliance with NYSE American Listing Standards
16/07/2026 -
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
16/07/2026 -
A breakthrough in coronary bypass surgery: AMT Medical’s SAFE-CAB results published in The Journal of Thoracic and Cardiovascular Surgery
16/07/2026 -
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
16/07/2026 -
Rinascera Therapeutics Launches with Clinical-Stage Pipeline to Transform the Treatment of Genetic Skin Diseases
16/07/2026 -
Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
16/07/2026 -
Sonus Microsystems’ Autonomous Ultrasound AI Platform Selected for Major ARPA-H Maternal Health Award
16/07/2026 -
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
16/07/2026 -
Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry’s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed/Refractory B Cell Malignancies
16/07/2026 -
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
16/07/2026 -
InnoCare Announces Phase II Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Vitiligo
16/07/2026
Pages